Drug bioavailability and pharmacokinetic analysis from pharmacological data
Conclusions The objective of pharmacotherapy is to control drug effects rather than drug levels. Direct chemical assay data are always of secondary interest and are of value only in that plasma levels often correlate with pharmacological or toxic response. The use of methodologies of control theory,...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Smolen, Victor F. [verfasserIn] Weigand, William A. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1973 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Journal of Pharmacokinetics and Biopharmaceutics - Kluwer Academic Publishers-Plenum Publishers, 1973, 1(1973), 4 vom: Aug., Seite 329-336 |
|---|---|
| Übergeordnetes Werk: |
volume:1 ; year:1973 ; number:4 ; month:08 ; pages:329-336 |
| Links: |
|---|
| DOI / URN: |
10.1007/BF01060040 |
|---|
| Katalog-ID: |
SPR01469445X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR01469445X | ||
| 003 | DE-627 | ||
| 005 | 20230519072602.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201006s1973 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/BF01060040 |2 doi | |
| 035 | |a (DE-627)SPR01469445X | ||
| 035 | |a (SPR)BF01060040-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Smolen, Victor F. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug bioavailability and pharmacokinetic analysis from pharmacological data |
| 264 | 1 | |c 1973 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Conclusions The objective of pharmacotherapy is to control drug effects rather than drug levels. Direct chemical assay data are always of secondary interest and are of value only in that plasma levels often correlate with pharmacological or toxic response. The use of methodologies of control theory, signal processing, and optimization, borrowed from engineering practice, allow the relations between drug inputs to be directly related to multiple, simultaneously occurring drug responses. These relations also permit time optimal drug inputs to be computed which optimize a multiple drug response behavior and represent a maximum therapeutic utility for the drug (8,9). In practice, such time optimal drug inputs may be achieved by programmed intravenous or other parenteral administration; such optimal response behavior may less precisely be realized through a predetermined dosage regimen with a drug product possessing the required dynamic drug bioavailability behavior. With the advent of increasingly more sophisticated biomedical recording and signal processing instrumentation and the increasing computerization of hospitals, it is not difficult to envisage that a maximum therapeutic utility of one or several drugs' actions may be automatically and continuously maintained using closed-loop feedback control. The process can be envisaged to involve monitoring of the patient's multiple drug responses and processing of the signals to compute an optimal pharmacotherapeutic control input signal, which in turn actuates servomechanistic drug-adminstering devices which deliver the drug(s) at the rate(s) required to maintain the patient's drug response behavior at optimal levels. In addition to the work now being pursued in the authors' laboratory, progress in approaching such ideals in pharmacotherapy is presently exemplified by the artificial “beta cell” developed by Whitaker Space Sciences which utilizes biofeedback controlled delivery of insulin in response to the patient's blood glucose levels. | ||
| 650 | 4 | |a Pharmacokinetic Analysis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug Bioavailability |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Systolic Time Interval |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pharmacological Data |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug Input |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Weigand, William A. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Pharmacokinetics and Biopharmaceutics |d Kluwer Academic Publishers-Plenum Publishers, 1973 |g 1(1973), 4 vom: Aug., Seite 329-336 |w (DE-627)SPR014694166 |7 nnns |
| 773 | 1 | 8 | |g volume:1 |g year:1973 |g number:4 |g month:08 |g pages:329-336 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/BF01060040 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_40 | ||
| 951 | |a AR | ||
| 952 | |d 1 |j 1973 |e 4 |c 08 |h 329-336 | ||
| author_variant |
v f s vf vfs w a w wa waw |
|---|---|
| matchkey_str |
smolenvictorfweigandwilliama:1973----:rgiaalbltadhraoieiaayifop |
| hierarchy_sort_str |
1973 |
| publishDate |
1973 |
| allfields |
10.1007/BF01060040 doi (DE-627)SPR01469445X (SPR)BF01060040-e DE-627 ger DE-627 rakwb eng Smolen, Victor F. verfasserin aut Drug bioavailability and pharmacokinetic analysis from pharmacological data 1973 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Conclusions The objective of pharmacotherapy is to control drug effects rather than drug levels. Direct chemical assay data are always of secondary interest and are of value only in that plasma levels often correlate with pharmacological or toxic response. The use of methodologies of control theory, signal processing, and optimization, borrowed from engineering practice, allow the relations between drug inputs to be directly related to multiple, simultaneously occurring drug responses. These relations also permit time optimal drug inputs to be computed which optimize a multiple drug response behavior and represent a maximum therapeutic utility for the drug (8,9). In practice, such time optimal drug inputs may be achieved by programmed intravenous or other parenteral administration; such optimal response behavior may less precisely be realized through a predetermined dosage regimen with a drug product possessing the required dynamic drug bioavailability behavior. With the advent of increasingly more sophisticated biomedical recording and signal processing instrumentation and the increasing computerization of hospitals, it is not difficult to envisage that a maximum therapeutic utility of one or several drugs' actions may be automatically and continuously maintained using closed-loop feedback control. The process can be envisaged to involve monitoring of the patient's multiple drug responses and processing of the signals to compute an optimal pharmacotherapeutic control input signal, which in turn actuates servomechanistic drug-adminstering devices which deliver the drug(s) at the rate(s) required to maintain the patient's drug response behavior at optimal levels. In addition to the work now being pursued in the authors' laboratory, progress in approaching such ideals in pharmacotherapy is presently exemplified by the artificial “beta cell” developed by Whitaker Space Sciences which utilizes biofeedback controlled delivery of insulin in response to the patient's blood glucose levels. Pharmacokinetic Analysis (dpeaa)DE-He213 Drug Bioavailability (dpeaa)DE-He213 Systolic Time Interval (dpeaa)DE-He213 Pharmacological Data (dpeaa)DE-He213 Drug Input (dpeaa)DE-He213 Weigand, William A. verfasserin aut Enthalten in Journal of Pharmacokinetics and Biopharmaceutics Kluwer Academic Publishers-Plenum Publishers, 1973 1(1973), 4 vom: Aug., Seite 329-336 (DE-627)SPR014694166 nnns volume:1 year:1973 number:4 month:08 pages:329-336 https://dx.doi.org/10.1007/BF01060040 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_40 AR 1 1973 4 08 329-336 |
| spelling |
10.1007/BF01060040 doi (DE-627)SPR01469445X (SPR)BF01060040-e DE-627 ger DE-627 rakwb eng Smolen, Victor F. verfasserin aut Drug bioavailability and pharmacokinetic analysis from pharmacological data 1973 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Conclusions The objective of pharmacotherapy is to control drug effects rather than drug levels. Direct chemical assay data are always of secondary interest and are of value only in that plasma levels often correlate with pharmacological or toxic response. The use of methodologies of control theory, signal processing, and optimization, borrowed from engineering practice, allow the relations between drug inputs to be directly related to multiple, simultaneously occurring drug responses. These relations also permit time optimal drug inputs to be computed which optimize a multiple drug response behavior and represent a maximum therapeutic utility for the drug (8,9). In practice, such time optimal drug inputs may be achieved by programmed intravenous or other parenteral administration; such optimal response behavior may less precisely be realized through a predetermined dosage regimen with a drug product possessing the required dynamic drug bioavailability behavior. With the advent of increasingly more sophisticated biomedical recording and signal processing instrumentation and the increasing computerization of hospitals, it is not difficult to envisage that a maximum therapeutic utility of one or several drugs' actions may be automatically and continuously maintained using closed-loop feedback control. The process can be envisaged to involve monitoring of the patient's multiple drug responses and processing of the signals to compute an optimal pharmacotherapeutic control input signal, which in turn actuates servomechanistic drug-adminstering devices which deliver the drug(s) at the rate(s) required to maintain the patient's drug response behavior at optimal levels. In addition to the work now being pursued in the authors' laboratory, progress in approaching such ideals in pharmacotherapy is presently exemplified by the artificial “beta cell” developed by Whitaker Space Sciences which utilizes biofeedback controlled delivery of insulin in response to the patient's blood glucose levels. Pharmacokinetic Analysis (dpeaa)DE-He213 Drug Bioavailability (dpeaa)DE-He213 Systolic Time Interval (dpeaa)DE-He213 Pharmacological Data (dpeaa)DE-He213 Drug Input (dpeaa)DE-He213 Weigand, William A. verfasserin aut Enthalten in Journal of Pharmacokinetics and Biopharmaceutics Kluwer Academic Publishers-Plenum Publishers, 1973 1(1973), 4 vom: Aug., Seite 329-336 (DE-627)SPR014694166 nnns volume:1 year:1973 number:4 month:08 pages:329-336 https://dx.doi.org/10.1007/BF01060040 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_40 AR 1 1973 4 08 329-336 |
| allfields_unstemmed |
10.1007/BF01060040 doi (DE-627)SPR01469445X (SPR)BF01060040-e DE-627 ger DE-627 rakwb eng Smolen, Victor F. verfasserin aut Drug bioavailability and pharmacokinetic analysis from pharmacological data 1973 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Conclusions The objective of pharmacotherapy is to control drug effects rather than drug levels. Direct chemical assay data are always of secondary interest and are of value only in that plasma levels often correlate with pharmacological or toxic response. The use of methodologies of control theory, signal processing, and optimization, borrowed from engineering practice, allow the relations between drug inputs to be directly related to multiple, simultaneously occurring drug responses. These relations also permit time optimal drug inputs to be computed which optimize a multiple drug response behavior and represent a maximum therapeutic utility for the drug (8,9). In practice, such time optimal drug inputs may be achieved by programmed intravenous or other parenteral administration; such optimal response behavior may less precisely be realized through a predetermined dosage regimen with a drug product possessing the required dynamic drug bioavailability behavior. With the advent of increasingly more sophisticated biomedical recording and signal processing instrumentation and the increasing computerization of hospitals, it is not difficult to envisage that a maximum therapeutic utility of one or several drugs' actions may be automatically and continuously maintained using closed-loop feedback control. The process can be envisaged to involve monitoring of the patient's multiple drug responses and processing of the signals to compute an optimal pharmacotherapeutic control input signal, which in turn actuates servomechanistic drug-adminstering devices which deliver the drug(s) at the rate(s) required to maintain the patient's drug response behavior at optimal levels. In addition to the work now being pursued in the authors' laboratory, progress in approaching such ideals in pharmacotherapy is presently exemplified by the artificial “beta cell” developed by Whitaker Space Sciences which utilizes biofeedback controlled delivery of insulin in response to the patient's blood glucose levels. Pharmacokinetic Analysis (dpeaa)DE-He213 Drug Bioavailability (dpeaa)DE-He213 Systolic Time Interval (dpeaa)DE-He213 Pharmacological Data (dpeaa)DE-He213 Drug Input (dpeaa)DE-He213 Weigand, William A. verfasserin aut Enthalten in Journal of Pharmacokinetics and Biopharmaceutics Kluwer Academic Publishers-Plenum Publishers, 1973 1(1973), 4 vom: Aug., Seite 329-336 (DE-627)SPR014694166 nnns volume:1 year:1973 number:4 month:08 pages:329-336 https://dx.doi.org/10.1007/BF01060040 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_40 AR 1 1973 4 08 329-336 |
| allfieldsGer |
10.1007/BF01060040 doi (DE-627)SPR01469445X (SPR)BF01060040-e DE-627 ger DE-627 rakwb eng Smolen, Victor F. verfasserin aut Drug bioavailability and pharmacokinetic analysis from pharmacological data 1973 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Conclusions The objective of pharmacotherapy is to control drug effects rather than drug levels. Direct chemical assay data are always of secondary interest and are of value only in that plasma levels often correlate with pharmacological or toxic response. The use of methodologies of control theory, signal processing, and optimization, borrowed from engineering practice, allow the relations between drug inputs to be directly related to multiple, simultaneously occurring drug responses. These relations also permit time optimal drug inputs to be computed which optimize a multiple drug response behavior and represent a maximum therapeutic utility for the drug (8,9). In practice, such time optimal drug inputs may be achieved by programmed intravenous or other parenteral administration; such optimal response behavior may less precisely be realized through a predetermined dosage regimen with a drug product possessing the required dynamic drug bioavailability behavior. With the advent of increasingly more sophisticated biomedical recording and signal processing instrumentation and the increasing computerization of hospitals, it is not difficult to envisage that a maximum therapeutic utility of one or several drugs' actions may be automatically and continuously maintained using closed-loop feedback control. The process can be envisaged to involve monitoring of the patient's multiple drug responses and processing of the signals to compute an optimal pharmacotherapeutic control input signal, which in turn actuates servomechanistic drug-adminstering devices which deliver the drug(s) at the rate(s) required to maintain the patient's drug response behavior at optimal levels. In addition to the work now being pursued in the authors' laboratory, progress in approaching such ideals in pharmacotherapy is presently exemplified by the artificial “beta cell” developed by Whitaker Space Sciences which utilizes biofeedback controlled delivery of insulin in response to the patient's blood glucose levels. Pharmacokinetic Analysis (dpeaa)DE-He213 Drug Bioavailability (dpeaa)DE-He213 Systolic Time Interval (dpeaa)DE-He213 Pharmacological Data (dpeaa)DE-He213 Drug Input (dpeaa)DE-He213 Weigand, William A. verfasserin aut Enthalten in Journal of Pharmacokinetics and Biopharmaceutics Kluwer Academic Publishers-Plenum Publishers, 1973 1(1973), 4 vom: Aug., Seite 329-336 (DE-627)SPR014694166 nnns volume:1 year:1973 number:4 month:08 pages:329-336 https://dx.doi.org/10.1007/BF01060040 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_40 AR 1 1973 4 08 329-336 |
| allfieldsSound |
10.1007/BF01060040 doi (DE-627)SPR01469445X (SPR)BF01060040-e DE-627 ger DE-627 rakwb eng Smolen, Victor F. verfasserin aut Drug bioavailability and pharmacokinetic analysis from pharmacological data 1973 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Conclusions The objective of pharmacotherapy is to control drug effects rather than drug levels. Direct chemical assay data are always of secondary interest and are of value only in that plasma levels often correlate with pharmacological or toxic response. The use of methodologies of control theory, signal processing, and optimization, borrowed from engineering practice, allow the relations between drug inputs to be directly related to multiple, simultaneously occurring drug responses. These relations also permit time optimal drug inputs to be computed which optimize a multiple drug response behavior and represent a maximum therapeutic utility for the drug (8,9). In practice, such time optimal drug inputs may be achieved by programmed intravenous or other parenteral administration; such optimal response behavior may less precisely be realized through a predetermined dosage regimen with a drug product possessing the required dynamic drug bioavailability behavior. With the advent of increasingly more sophisticated biomedical recording and signal processing instrumentation and the increasing computerization of hospitals, it is not difficult to envisage that a maximum therapeutic utility of one or several drugs' actions may be automatically and continuously maintained using closed-loop feedback control. The process can be envisaged to involve monitoring of the patient's multiple drug responses and processing of the signals to compute an optimal pharmacotherapeutic control input signal, which in turn actuates servomechanistic drug-adminstering devices which deliver the drug(s) at the rate(s) required to maintain the patient's drug response behavior at optimal levels. In addition to the work now being pursued in the authors' laboratory, progress in approaching such ideals in pharmacotherapy is presently exemplified by the artificial “beta cell” developed by Whitaker Space Sciences which utilizes biofeedback controlled delivery of insulin in response to the patient's blood glucose levels. Pharmacokinetic Analysis (dpeaa)DE-He213 Drug Bioavailability (dpeaa)DE-He213 Systolic Time Interval (dpeaa)DE-He213 Pharmacological Data (dpeaa)DE-He213 Drug Input (dpeaa)DE-He213 Weigand, William A. verfasserin aut Enthalten in Journal of Pharmacokinetics and Biopharmaceutics Kluwer Academic Publishers-Plenum Publishers, 1973 1(1973), 4 vom: Aug., Seite 329-336 (DE-627)SPR014694166 nnns volume:1 year:1973 number:4 month:08 pages:329-336 https://dx.doi.org/10.1007/BF01060040 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_40 AR 1 1973 4 08 329-336 |
| language |
English |
| source |
Enthalten in Journal of Pharmacokinetics and Biopharmaceutics 1(1973), 4 vom: Aug., Seite 329-336 volume:1 year:1973 number:4 month:08 pages:329-336 |
| sourceStr |
Enthalten in Journal of Pharmacokinetics and Biopharmaceutics 1(1973), 4 vom: Aug., Seite 329-336 volume:1 year:1973 number:4 month:08 pages:329-336 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Pharmacokinetic Analysis Drug Bioavailability Systolic Time Interval Pharmacological Data Drug Input |
| isfreeaccess_bool |
false |
| container_title |
Journal of Pharmacokinetics and Biopharmaceutics |
| authorswithroles_txt_mv |
Smolen, Victor F. @@aut@@ Weigand, William A. @@aut@@ |
| publishDateDaySort_date |
1973-08-01T00:00:00Z |
| hierarchy_top_id |
SPR014694166 |
| id |
SPR01469445X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR01469445X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519072602.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s1973 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF01060040</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR01469445X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF01060040-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Smolen, Victor F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug bioavailability and pharmacokinetic analysis from pharmacological data</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1973</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Conclusions The objective of pharmacotherapy is to control drug effects rather than drug levels. Direct chemical assay data are always of secondary interest and are of value only in that plasma levels often correlate with pharmacological or toxic response. The use of methodologies of control theory, signal processing, and optimization, borrowed from engineering practice, allow the relations between drug inputs to be directly related to multiple, simultaneously occurring drug responses. These relations also permit time optimal drug inputs to be computed which optimize a multiple drug response behavior and represent a maximum therapeutic utility for the drug (8,9). In practice, such time optimal drug inputs may be achieved by programmed intravenous or other parenteral administration; such optimal response behavior may less precisely be realized through a predetermined dosage regimen with a drug product possessing the required dynamic drug bioavailability behavior. With the advent of increasingly more sophisticated biomedical recording and signal processing instrumentation and the increasing computerization of hospitals, it is not difficult to envisage that a maximum therapeutic utility of one or several drugs' actions may be automatically and continuously maintained using closed-loop feedback control. The process can be envisaged to involve monitoring of the patient's multiple drug responses and processing of the signals to compute an optimal pharmacotherapeutic control input signal, which in turn actuates servomechanistic drug-adminstering devices which deliver the drug(s) at the rate(s) required to maintain the patient's drug response behavior at optimal levels. In addition to the work now being pursued in the authors' laboratory, progress in approaching such ideals in pharmacotherapy is presently exemplified by the artificial “beta cell” developed by Whitaker Space Sciences which utilizes biofeedback controlled delivery of insulin in response to the patient's blood glucose levels.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacokinetic Analysis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Bioavailability</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Systolic Time Interval</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacological Data</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Input</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weigand, William A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of Pharmacokinetics and Biopharmaceutics</subfield><subfield code="d">Kluwer Academic Publishers-Plenum Publishers, 1973</subfield><subfield code="g">1(1973), 4 vom: Aug., Seite 329-336</subfield><subfield code="w">(DE-627)SPR014694166</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:1973</subfield><subfield code="g">number:4</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:329-336</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF01060040</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">1973</subfield><subfield code="e">4</subfield><subfield code="c">08</subfield><subfield code="h">329-336</subfield></datafield></record></collection>
|
| author |
Smolen, Victor F. |
| spellingShingle |
Smolen, Victor F. misc Pharmacokinetic Analysis misc Drug Bioavailability misc Systolic Time Interval misc Pharmacological Data misc Drug Input Drug bioavailability and pharmacokinetic analysis from pharmacological data |
| authorStr |
Smolen, Victor F. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR014694166 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Drug bioavailability and pharmacokinetic analysis from pharmacological data Pharmacokinetic Analysis (dpeaa)DE-He213 Drug Bioavailability (dpeaa)DE-He213 Systolic Time Interval (dpeaa)DE-He213 Pharmacological Data (dpeaa)DE-He213 Drug Input (dpeaa)DE-He213 |
| topic |
misc Pharmacokinetic Analysis misc Drug Bioavailability misc Systolic Time Interval misc Pharmacological Data misc Drug Input |
| topic_unstemmed |
misc Pharmacokinetic Analysis misc Drug Bioavailability misc Systolic Time Interval misc Pharmacological Data misc Drug Input |
| topic_browse |
misc Pharmacokinetic Analysis misc Drug Bioavailability misc Systolic Time Interval misc Pharmacological Data misc Drug Input |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of Pharmacokinetics and Biopharmaceutics |
| hierarchy_parent_id |
SPR014694166 |
| hierarchy_top_title |
Journal of Pharmacokinetics and Biopharmaceutics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR014694166 |
| title |
Drug bioavailability and pharmacokinetic analysis from pharmacological data |
| ctrlnum |
(DE-627)SPR01469445X (SPR)BF01060040-e |
| title_full |
Drug bioavailability and pharmacokinetic analysis from pharmacological data |
| author_sort |
Smolen, Victor F. |
| journal |
Journal of Pharmacokinetics and Biopharmaceutics |
| journalStr |
Journal of Pharmacokinetics and Biopharmaceutics |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1973 |
| contenttype_str_mv |
txt |
| container_start_page |
329 |
| author_browse |
Smolen, Victor F. Weigand, William A. |
| container_volume |
1 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Smolen, Victor F. |
| doi_str_mv |
10.1007/BF01060040 |
| author2-role |
verfasserin |
| title_sort |
drug bioavailability and pharmacokinetic analysis from pharmacological data |
| title_auth |
Drug bioavailability and pharmacokinetic analysis from pharmacological data |
| abstract |
Conclusions The objective of pharmacotherapy is to control drug effects rather than drug levels. Direct chemical assay data are always of secondary interest and are of value only in that plasma levels often correlate with pharmacological or toxic response. The use of methodologies of control theory, signal processing, and optimization, borrowed from engineering practice, allow the relations between drug inputs to be directly related to multiple, simultaneously occurring drug responses. These relations also permit time optimal drug inputs to be computed which optimize a multiple drug response behavior and represent a maximum therapeutic utility for the drug (8,9). In practice, such time optimal drug inputs may be achieved by programmed intravenous or other parenteral administration; such optimal response behavior may less precisely be realized through a predetermined dosage regimen with a drug product possessing the required dynamic drug bioavailability behavior. With the advent of increasingly more sophisticated biomedical recording and signal processing instrumentation and the increasing computerization of hospitals, it is not difficult to envisage that a maximum therapeutic utility of one or several drugs' actions may be automatically and continuously maintained using closed-loop feedback control. The process can be envisaged to involve monitoring of the patient's multiple drug responses and processing of the signals to compute an optimal pharmacotherapeutic control input signal, which in turn actuates servomechanistic drug-adminstering devices which deliver the drug(s) at the rate(s) required to maintain the patient's drug response behavior at optimal levels. In addition to the work now being pursued in the authors' laboratory, progress in approaching such ideals in pharmacotherapy is presently exemplified by the artificial “beta cell” developed by Whitaker Space Sciences which utilizes biofeedback controlled delivery of insulin in response to the patient's blood glucose levels. |
| abstractGer |
Conclusions The objective of pharmacotherapy is to control drug effects rather than drug levels. Direct chemical assay data are always of secondary interest and are of value only in that plasma levels often correlate with pharmacological or toxic response. The use of methodologies of control theory, signal processing, and optimization, borrowed from engineering practice, allow the relations between drug inputs to be directly related to multiple, simultaneously occurring drug responses. These relations also permit time optimal drug inputs to be computed which optimize a multiple drug response behavior and represent a maximum therapeutic utility for the drug (8,9). In practice, such time optimal drug inputs may be achieved by programmed intravenous or other parenteral administration; such optimal response behavior may less precisely be realized through a predetermined dosage regimen with a drug product possessing the required dynamic drug bioavailability behavior. With the advent of increasingly more sophisticated biomedical recording and signal processing instrumentation and the increasing computerization of hospitals, it is not difficult to envisage that a maximum therapeutic utility of one or several drugs' actions may be automatically and continuously maintained using closed-loop feedback control. The process can be envisaged to involve monitoring of the patient's multiple drug responses and processing of the signals to compute an optimal pharmacotherapeutic control input signal, which in turn actuates servomechanistic drug-adminstering devices which deliver the drug(s) at the rate(s) required to maintain the patient's drug response behavior at optimal levels. In addition to the work now being pursued in the authors' laboratory, progress in approaching such ideals in pharmacotherapy is presently exemplified by the artificial “beta cell” developed by Whitaker Space Sciences which utilizes biofeedback controlled delivery of insulin in response to the patient's blood glucose levels. |
| abstract_unstemmed |
Conclusions The objective of pharmacotherapy is to control drug effects rather than drug levels. Direct chemical assay data are always of secondary interest and are of value only in that plasma levels often correlate with pharmacological or toxic response. The use of methodologies of control theory, signal processing, and optimization, borrowed from engineering practice, allow the relations between drug inputs to be directly related to multiple, simultaneously occurring drug responses. These relations also permit time optimal drug inputs to be computed which optimize a multiple drug response behavior and represent a maximum therapeutic utility for the drug (8,9). In practice, such time optimal drug inputs may be achieved by programmed intravenous or other parenteral administration; such optimal response behavior may less precisely be realized through a predetermined dosage regimen with a drug product possessing the required dynamic drug bioavailability behavior. With the advent of increasingly more sophisticated biomedical recording and signal processing instrumentation and the increasing computerization of hospitals, it is not difficult to envisage that a maximum therapeutic utility of one or several drugs' actions may be automatically and continuously maintained using closed-loop feedback control. The process can be envisaged to involve monitoring of the patient's multiple drug responses and processing of the signals to compute an optimal pharmacotherapeutic control input signal, which in turn actuates servomechanistic drug-adminstering devices which deliver the drug(s) at the rate(s) required to maintain the patient's drug response behavior at optimal levels. In addition to the work now being pursued in the authors' laboratory, progress in approaching such ideals in pharmacotherapy is presently exemplified by the artificial “beta cell” developed by Whitaker Space Sciences which utilizes biofeedback controlled delivery of insulin in response to the patient's blood glucose levels. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_40 |
| container_issue |
4 |
| title_short |
Drug bioavailability and pharmacokinetic analysis from pharmacological data |
| url |
https://dx.doi.org/10.1007/BF01060040 |
| remote_bool |
true |
| author2 |
Weigand, William A. |
| author2Str |
Weigand, William A. |
| ppnlink |
SPR014694166 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/BF01060040 |
| up_date |
2024-07-04T02:44:43.476Z |
| _version_ |
1803614770667978752 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR01469445X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519072602.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s1973 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF01060040</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR01469445X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF01060040-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Smolen, Victor F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug bioavailability and pharmacokinetic analysis from pharmacological data</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1973</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Conclusions The objective of pharmacotherapy is to control drug effects rather than drug levels. Direct chemical assay data are always of secondary interest and are of value only in that plasma levels often correlate with pharmacological or toxic response. The use of methodologies of control theory, signal processing, and optimization, borrowed from engineering practice, allow the relations between drug inputs to be directly related to multiple, simultaneously occurring drug responses. These relations also permit time optimal drug inputs to be computed which optimize a multiple drug response behavior and represent a maximum therapeutic utility for the drug (8,9). In practice, such time optimal drug inputs may be achieved by programmed intravenous or other parenteral administration; such optimal response behavior may less precisely be realized through a predetermined dosage regimen with a drug product possessing the required dynamic drug bioavailability behavior. With the advent of increasingly more sophisticated biomedical recording and signal processing instrumentation and the increasing computerization of hospitals, it is not difficult to envisage that a maximum therapeutic utility of one or several drugs' actions may be automatically and continuously maintained using closed-loop feedback control. The process can be envisaged to involve monitoring of the patient's multiple drug responses and processing of the signals to compute an optimal pharmacotherapeutic control input signal, which in turn actuates servomechanistic drug-adminstering devices which deliver the drug(s) at the rate(s) required to maintain the patient's drug response behavior at optimal levels. In addition to the work now being pursued in the authors' laboratory, progress in approaching such ideals in pharmacotherapy is presently exemplified by the artificial “beta cell” developed by Whitaker Space Sciences which utilizes biofeedback controlled delivery of insulin in response to the patient's blood glucose levels.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacokinetic Analysis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Bioavailability</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Systolic Time Interval</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacological Data</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Input</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weigand, William A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of Pharmacokinetics and Biopharmaceutics</subfield><subfield code="d">Kluwer Academic Publishers-Plenum Publishers, 1973</subfield><subfield code="g">1(1973), 4 vom: Aug., Seite 329-336</subfield><subfield code="w">(DE-627)SPR014694166</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:1973</subfield><subfield code="g">number:4</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:329-336</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF01060040</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">1973</subfield><subfield code="e">4</subfield><subfield code="c">08</subfield><subfield code="h">329-336</subfield></datafield></record></collection>
|
| score |
7.4016542 |